Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Cardiff Oncology, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 117
- +34 vs. Q3 2024
- Shares held
- 28.1M
- +15.3M (+120.1%) vs. Q3 2024
- Total value
- $121.9M
- +$87.8M (+257.8%) vs. Q3 2024
- New holders
- 37
- 40 more added
- Sold out
- 3
- 16 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRDF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $24.2M |
| Q1 2026 | 117 | $39.7M |
| Q4 2025 | 110 | $76.6M |
| Q3 2025 | 112 | $51.9M |
| Q2 2025 | 115 | $90.3M |
| Q1 2025 | 116 | $101.6M |
| Q4 2024 | 117 | $121.9M |
| Q3 2024 | 83 | $34.1M |
| Q2 2024 | 90 | $29.1M |
| Q1 2024 | 77 | $45.8M |
| Q4 2023 | 55 | $7.84M |
| Q3 2023 | 56 | $7.58M |
| Q2 2023 | 53 | $8.81M |
| Q1 2023 | 55 | $11.6M |
| Q4 2022 | 60 | $10.8M |
| Q3 2022 | 58 | $12.2M |
| Q2 2022 | 67 | $19.6M |
| Q1 2022 | 91 | $41.0M |
| Q4 2021 | 87 | $132.1M |
| Q3 2021 | 94 | $140.7M |
| Q2 2021 | 90 | $176.4M |
| Q1 2021 | 73 | $223.0M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Cardiff Oncology, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 440,944 | $1.91M | 0.00% | +288,259+188.8% | Added |
| Ikarian Capital, LLC | 450,000 | $1.95M | 0.56% | +450,000 | New |
| Renaissance Technologies LLC | 483,090 | $2.10M | 0.00% | −119,294−19.8% | Reduced |
| Point72 Asset Management, L.P. | 508,438 | $2.21M | 0.01% | +508,438 | New |
| Morgan Stanley | 542,389 | $2.35M | 0.00% | +44,247+8.9% | Added |
| Laurion Capital Management LP | 576,924 | $2.50M | 0.16% | +576,924 | New |
| Nuveen Asset Management, LLC | 586,616 | $2.55M | 0.00% | +248,850+73.7% | Added |
| State Street Corp | 848,579 | $3.68M | 0.00% | +15,927+1.9% | Added |
| MAI Capital Management | 916,587 | $3.98M | 0.03% | +253,224+38.2% | Added |
| Geode Capital Management, LLC | 982,878 | $4.27M | 0.00% | +54,646+5.9% | Added |
| Adage Capital Partners GP, L.L.C. | 1,292,308 | $5.61M | 0.01% | +1,292,308 | New |
| Acorn Capital Advisors, LLC | 1,442,308 | $6.26M | 3.37% | +1,442,308 | New |
| OrbiMed Advisors LLC | 1,538,462 | $6.68M | 0.14% | +1,538,462 | New |
| Vanguard Group Inc | 2,284,917 | $9.92M | 0.00% | +113,473+5.2% | Added |
| Pfizer Inc | 2,411,575 | $10.5M | 0.40% | +2,411,575 | New |
| BlackRock, Inc. | 2,840,909 | $12.3M | 0.00% | +105,328+3.9% | Added |
| Commodore Capital LP | 5,384,616 | $23.4M | 1.71% | +5,384,616 | New |
| BIT Capital GmbH | 0 | $0 | 0.00% | −253,085−100.0% | Sold out |
| Cetera Investment Advisers | 0 | $0 | 0.00% | −38,000−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −37,245−100.0% | Sold out |